Advertisement
NVS vs SNY
Which Stock Would AI Choose? Novartis AG (NVS) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- NVS has outperformed SNY year-to-date with a 12.16% return compared to SNY's 1.54%, driven by strong momentum in recent market activity.
- Both stocks offer attractive dividends, with SNY providing a higher yield of 5.05% versus NVS's 3.14%.
- NVS boasts a larger market capitalization of approximately $291 billion, reflecting greater scale than SNY's $115 billion.
- Recent developments, including positive clinical data for NVS's Fabhalta and approvals for SNY's Dupixent, highlight ongoing innovation in both portfolios.
- SNY exhibits lower volatility with a beta of 0.32 (a measure of stock volatility relative to the market), compared to NVS's 0.52.
- Price-to-earnings (P/E) ratios are similar at around 21 for NVS and 20 for SNY, indicating comparable valuations.
Introduction
Novartis AG (NVS) and Sanofi (SNY) are two leading pharmaceutical giants with global footprints in drug development and commercialization. This stock comparison is particularly relevant for investors seeking exposure to the healthcare sector, including those focused on dividend income, long-term growth, or relative performance amid evolving market conditions. Both companies navigate patent cliffs, regulatory approvals, and innovation pipelines, making their head-to-head analysis valuable for portfolio diversification and trend assessment in recent market activity.
NVS Overview and Recent Performance
Novartis AG (NVS), headquartered in Basel, Switzerland, specializes in innovative medicines across cardiovascular, oncology, immunology, neuroscience, and hematology. Key products include Entresto for heart failure, Cosentyx for psoriasis, and Kisqali for breast cancer. In recent weeks, NVS shares have traded around $151, within a 52-week range of $105 to $170, supported by a market cap exceeding $290 billion. Year-to-date gains of 12% and one-year returns of 40% reflect positive sentiment from Q4 earnings beats, Fabhalta data in IgA nephropathy, and increased M&A activity in pharma. Generic pressures on Entresto have been offset by pipeline momentum, contributing to stable performance and a P/E ratio of 21.
SNY Overview and Recent Performance
Sanofi (SNY), based in Paris, France, focuses on immunology, vaccines, rare diseases, neurology, and oncology, with standout products like Dupixent for inflammation and various vaccines. Shares have hovered near $48, in a 52-week range of $43 to $56, with a market cap of about $115 billion. Recent market activity shows modest YTD gains of 1.5%, influenced by Dupixent expansions in pediatrics and urticaria, alongside RSV vaccine progress. However, leadership changes and revenue expiry concerns have tempered momentum, yielding a P/E of 20 and higher dividend appeal amid quarterly revenue growth of nearly 7%.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top-performing AI trading bots from a library of over 350 bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions—based on volatility, performance, and strategy—earn a spot among the 25 featured trending agents. These bots showcase impressive stats, such as annualized returns ranging from 30% to over 120%, win rates of 55-87%, profit factors up to 6.94, and profit-to-drawdown ratios exceeding 10 in some cases. Strategies vary from swing trading dips in industrials to semiconductor momentum on 5-60 minute timeframes, with examples trading NVDA, SOXL, or LRCX. Explore these for diverse styles and real-time signals tailored to today's environment.
Head-to-Head Comparison
Both NVS and SNY operate in pharmaceuticals but differ in focus: NVS emphasizes oncology and cardiology blockbusters, while SNY leads in vaccines and immunology via Dupixent partnerships. Growth drivers include NVS's pipeline catalysts like Fabhalta versus SNY's regulatory wins, though NVS shows superior recent momentum with higher YTD returns. Risk profiles contrast with SNY's lower beta offering stability, balanced against NVS's scale advantages. Market sentiment favors NVS for trend strength amid sector M&A, while SNY appeals for yield in defensive positioning.
Tickeron AI Verdict
Tickeron's AI models currently lean toward NVS due to its consistent upward trends, robust YTD outperformance, and favorable positioning from recent clinical and earnings catalysts. While SNY offers higher yield and lower volatility, NVS exhibits stronger relative momentum and scale, suggesting higher probability of near-term gains in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Hold and SNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 3 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- NVS’s FA Score: 3 green, 2 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 5 TA indicator(s) are bullish while SNY’s TA Score has 2 bullish TA indicator(s).
- NVS’s TA Score: 5 bullish, 4 bearish.
- SNY’s TA Score: 2 bullish, 8 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а -4.44% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
NVS is expected to report earnings on Jul 21, 2026.
SNY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NVS | SNY | NVS / SNY | |
| Capitalization | 282B | 101B | 279% |
| EBITDA | 22.4B | 8.52B | 263% |
| Gain YTD | 9.904 | -7.701 | -129% |
| P/E Ratio | 21.07 | 18.43 | 114% |
| Revenue | 56.6B | 47.4B | 119% |
| Total Cash | 6.98B | 5.54B | 126% |
| Total Debt | 47B | 20B | 235% |
NVS | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 100 | |
SMR RATING 1..100 | 27 | 71 | |
PRICE GROWTH RATING 1..100 | 51 | 60 | |
P/E GROWTH RATING 1..100 | 37 | 41 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as NVS (6). This means that SNY’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for SNY (100). This means that NVS’s stock grew significantly faster than SNY’s over the last 12 months.
NVS's SMR Rating (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (71). This means that NVS’s stock grew somewhat faster than SNY’s over the last 12 months.
NVS's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that NVS’s stock grew similarly to SNY’s over the last 12 months.
NVS's P/E Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as SNY (41). This means that NVS’s stock grew similarly to SNY’s over the last 12 months.
| NVS | SNY | |
|---|---|---|
| RSI ODDS (%) | N/A | 20 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 51% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 55% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 47% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 43% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 39% | 3 days ago 43% |
| Advances ODDS (%) | 16 days ago 51% | 9 days ago 50% |
| Declines ODDS (%) | 3 days ago 45% | 3 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 44% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 47% | 3 days ago 55% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then NVS could also see price increases.